Department of Radiology.
Department of Gynaecology.
Surg Laparosc Endosc Percutan Tech. 2020 Jun;30(3):281-284. doi: 10.1097/SLE.0000000000000780.
To evaluate the clinical effectiveness and long-term outcomes of unilateral stent insertion with high-intensity focused ultrasound ablation (HIFUA) in patients with hilar cholangiocarcinoma (HCCA).
From March 2016 to June 2019, consecutive patients presenting with HCCA were treated with single stent insertion or stent with HIFUA. The long-term outcomes of the 2 groups were compared.
During the study period, 37 patients were included who underwent single stent insertion and 32 patients who underwent stent insertion with HIFUA. Eight (21.6%) patients in the single stent group and 6 (18.8%) in the combined group experienced stent dysfunction (P=0.767). Median stent patency in the single stent and combined groups was 169 and 225 days, respectively (P<0.001). All patients died because of tumor progression. The median poststent overall survival for patients in the single stent and combined groups were 178 and 246 days, respectively (P<0.001).
HIFUA after unilateral stent insertion can prolong stent patency and survival of patients with inoperable HCCA.
评估高强度聚焦超声消融（HIFUA）联合单侧支架置入治疗肝门部胆管癌（HCCA）的临床疗效和长期预后。
2016 年 3 月至 2019 年 6 月，连续入组接受单纯支架置入或支架联合 HIFUA 治疗的 HCCA 患者。比较两组的长期预后。
研究期间，37 例患者接受单纯支架置入，32 例患者接受支架联合 HIFUA 治疗。单纯支架组 8 例（21.6%）和联合组 6 例（18.8%）出现支架功能障碍（P=0.767）。单纯支架组和联合组中位支架通畅时间分别为 169 天和 225 天（P<0.001）。所有患者均因肿瘤进展而死亡。单纯支架组和联合组中位支架后总生存时间分别为 178 天和 246 天（P<0.001）。
HIFUA 联合单侧支架置入可延长不可切除的 HCCA 患者的支架通畅时间和生存时间。
